Skip to main content
SpringerLink
Log in

Docetaxel cost effective for oesophagogastric cancer?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 British pounds except for docetaxel price (2013)

  2. National Institute for Health and Care Excellence

Reference

  • Meads DM, et al. The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial. PharmacoEconomics : 4 Sep 2015. Available from: URL: http://doi.org/10.1007/s40273-015-0324-5

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Docetaxel cost effective for oesophagogastric cancer?. PharmacoEcon Outcomes News 736, 12 (2015). https://doi.org/10.1007/s40274-015-2422-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2422-1

Search

Navigation